Atrion Co. (NASDAQ:ATRI) has received a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation.
Zacks has also given Atrion an industry rank of 122 out of 265 based on the ratings given to related companies.
Separately, BidaskClub cut shares of Atrion from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th.
Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Atrion in the 4th quarter worth approximately $269,000. Teacher Retirement System of Texas purchased a new stake in shares of Atrion in the 4th quarter worth approximately $323,000. Bank of Montreal Can lifted its position in Atrion by 25.7% during the fourth quarter. Bank of Montreal Can now owns 597 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 122 shares during the last quarter. Voya Investment Management LLC lifted its position in Atrion by 10.2% during the second quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock valued at $486,000 after acquiring an additional 70 shares during the last quarter. Finally, Advisor Group Inc. lifted its position in Atrion by 5,826.7% during the third quarter. Advisor Group Inc. now owns 889 shares of the medical instruments supplier’s stock valued at $598,000 after acquiring an additional 874 shares during the last quarter. 58.84% of the stock is owned by hedge funds and other institutional investors.
Shares of Atrion (ATRI) opened at $561.25 on Wednesday. Atrion has a 52-week low of $459.05 and a 52-week high of $694.00. The firm has a market cap of $1,048.14, a P/E ratio of 31.09 and a beta of 0.73.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/zacks-atrion-co-atri-receives-average-rating-of-strong-sell-from-analysts.html.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Get a free copy of the Zacks research report on Atrion (ATRI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.